Neurizon Expands ALS Trial Cohort to 240 with Faster Completion Target

Trial Expansion Reflects Strong Recruitment Momentum

Neurizon Therapeutics Limited (ASX:NUZ) has increased the size of Regimen I in its HEALEY ALS Platform Trial from 160 to 240 participants. This 50% expansion is driven by enrolment rates exceeding expectations and the absence of competing regimens during the recruitment period. The boost preserves the statistical power for the primary endpoint and enables more detailed subgroup and biomarker analyses, strengthening the trial's scientific rigour.

As of 22 May 2026, 113 participants have been assigned and 74 dosed across 64 activated US clinical sites, with 193 screened under the master protocol. The rapid pace of enrolment builds on Neurizon’s earlier milestones, including the initial dosing in this pivotal Phase 2/3 trial earlier this year, which marked a critical step in advancing NUZ-001’s clinical development Phase 2/3 trial dosing.

Accelerated Timeline Despite Larger Cohort

Interestingly, the larger sample size is expected to speed up the overall trial timeline rather than delay it. Neurizon now anticipates last participant dosing in the second quarter of calendar year 2027, with topline results to be reported early in the third quarter. This surpasses prior projections despite the increased recruitment target, reflecting the company’s confidence in the recruitment momentum and trial execution.

The expanded design comprises 180 participants receiving NUZ-001 and 60 placebo controls, maintaining the original statistical assumptions underpinning the study. This internally consistent dataset eliminates reliance on placebo groups from other regimens, which could complicate interpretation.

Cost Management and Philanthropic Support

Crucially for investors wary of ballooning clinical costs, Neurizon reports that the expansion will have no impact on its funding requirements through to topline results. The increased participant numbers are materially offset by philanthropic contributions from the Sean M. Healey & AMG Center for ALS at Mass General Brigham, alongside diligent cost management and eligibility for the Australian Federal Government’s R&D Tax Incentive Program.

This financial discipline ensures only a modest increase in the total cost of completing the full trial, reinforcing Neurizon’s commitment to capital efficiency as it advances NUZ-001. The company remains fully funded through trial completion, a reassuring signal amid the high costs typical of late-stage neurodegenerative disease trials.

Strategic Implications for NUZ-001 Development

Interim Executive Chairman Sergio Duchini emphasised that the expansion reflects strong confidence in NUZ-001 and the HEALEY ALS Platform Trial’s network. A larger, more statistically robust dataset is expected to enhance the interpretability and strategic value of the program, potentially improving regulatory, partnering, and commercial opportunities.

Neurizon’s approach aligns with the broader trend of adaptive platform trials in neurodegenerative diseases, which aim to accelerate development timelines and improve data quality. The company’s focus on biomarker and translational insights could also position NUZ-001 favorably in a competitive ALS landscape.

The partnership with the Sean M. Healey & AMG Center and the Network of Excellence for ALS (NEALS) underscores a collaborative effort to accelerate progress in this area of urgent unmet medical need, as highlighted by key investigators involved in the trial.

Neurizon plans a shareholder webinar on 28 May 2026 to discuss the expanded enrolment and provide further context, signalling transparency and engagement with its investor base. This follows recent corporate developments, including a successful capital raise that bolstered the company's financial flexibility to support NUZ-001’s clinical advancement capital raise.